Results 101 to 110 of about 709,715 (218)

Highly sensitive SERS quantification of organophosphorous chemical warfare agents: A major step towards the real time sensing in the gas phase

, 2018
Marta Lafuente, Ismael Pellejero, Víctor Sebastián, Miguel Urbiztondo, Reyes Mallada, M.P. Pina, Jesús Santamarı́a   +6 more
openalex   +2 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

ACEGEN: Reinforcement Learning of Generative Chemical Agents for Drug Discovery. [PDF]

J Chem Inf Model
Bou A, Thomas M, Dittert S, Navarro C, Majewski M, Wang Y, Patel S, Tresadern G, Ahmad M, Moens V, Sherman W, Sciabola S, De Fabritiis G.   +12 more
europepmc   +1 more source

Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action

, 2016
Peter V. Danenberg, Bengt Gustavsson, Patrick Johnston, Per Lindberg, Rudolf Moser, Elisabeth Odin, Godefridus J. Peters, Nicholas J. Petrelli   +7 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Environmental and Occupational Exposure to Chemical Agents and Health Challenges I-What Message Can Bring to Regulatory Science? [PDF]

Toxics
Ladeira C.
europepmc   +1 more source

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

Molecular Oncology, EarlyView.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker, Elysia Sarsam, Stuart J. Conway, Ester M. Hammond   +3 more
wiley   +1 more source

A Novel Machine Learning Model and a Web Portal for Predicting the Human Skin Sensitization Effects of Chemical Agents. [PDF]

Toxics
Scheufen Tieghi R, Moreira-Filho JT, Martin HJ, Wellnitz J, Otoch MC, Rath M, Tropsha A, Muratov EN, Kleinstreuer N.   +8 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Microhardness and characterization of human dental tissue after application of enzymatic chemical agents: In vitro study. [PDF]

J Clin Exp Dent
Lins-Candeiro CL, Batista-de-Souza W, Navarro-de-Oliveira M, Santos-Filho PC, Paranhos LR.   +4 more
europepmc   +1 more source